🧬 BioMed Pulse · 2026-11-15 02:01 UTC

BIOMED PULSE

Sunday, November 15, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo remains the defining global health emergency of our time, now the largest Ebola-family outbreak ever recorded, with sustained transmission spreading into new provinces and imported cases confirmed in Kenya and Nigeria. Mood: urgent — multiple simultaneous outbreak fronts, cautious longevity science signals, and a steady pipeline of generic drug actions.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (BVD) — DRC, KENYA, NIGERIA

  • As of the November 6 WHO Disease Outbreak News, the BVD outbreak in the DRC continues with sustained high-level transmission across multiple health zones, with Kenya and Nigeria also reporting imported cases. [1]
  • The outbreak has expanded within the DRC since the last update on October 23, with geographic spread to additional health zones accelerating; this remains the largest Ebola-family outbreak ever reported in the DRC. [1][2]
  • An imported BVD case was confirmed in Kenya on October 5 in a patient with travel history from DRC through Uganda, underscoring cross-border spillover risk. [3]

MERS-CoV — QATAR

  • On October 29, 2026, Qatar's National IHR Focal Point notified WHO of two laboratory-confirmed MERS-CoV cases, confirmed August 5 and August 25, marking the first MERS cases ever reported from Qatar. [4]
  • Between January 1 and October 5, Saudi Arabia separately reported eight laboratory-confirmed MERS-CoV cases including one death across six locations including Riyadh and Tabuk. [5]
  • No human-to-human transmission chains have been announced; camel exposure remains the presumed route in both countries. [5][4]

SHAMONDA VIRUS — FRANCE (FIRST HUMAN CASE)

  • On October 20, 2026, France notified WHO of the world's first documented human infection with Shamonda virus, a Bunyavirus, in an immunocompromised older man from eastern France with no recent travel history. [6]
  • The patient developed severe neurological symptoms; Shamonda virus had previously only been detected in animals, making this a significant novel pathogen event. [6]
  • CDC samples were requested for additional viral characterization; surveillance for further human cases is ongoing. [6]

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA

  • On October 2, 2026, WHO was alerted via media reports to the death of an employee at the Irkutsk Antiplague Research Institute of Siberia following severe pneumonia; etiology remains undetermined. [7]
  • The institutional setting — a biosafety research facility — raises biosafety questions, though WHO has not yet confirmed a laboratory-acquired infection. [7]

YELLOW FEVER — AFRICA

  • Between January 1 and October 12, 2026, the WHO African Region recorded 67 confirmed yellow fever cases including 18 deaths across nine countries, including Burkina Faso, Cameroon, Central African Republic, and others. [8]
  • Transmission activity in the Americas also continued into 2026, with six countries reporting 79 human infections between January 1 and May 26, 2026. [9]

🧬 LONGEVITY & AGING

GDF11 AND MUSCLE AGING

  • A new study in Genes and Disease (Zhang F., published February 2026) found that the circulating protein GDF11 restores the function of skeletal muscle satellite cells — the stem cells responsible for muscle repair — through the MYC transcription factor pathway, ameliorating sarcopenia in a research model. [10]
  • Sarcopenia (age-related muscle wasting) is a leading driver of frailty, falls, and loss of independence in older adults, making GDF11 a continuing target of geroscience interest. [10]

mTORC1 INHIBITION FOR DISC DEGENERATION

  • Researchers published in Bioactive Materials report that cationized gelatin nanospheres delivering RNA interference targeting mTORC1 — a key cellular aging and nutrient-sensing pathway — protected against intervertebral disc degeneration in a controlled release system.
  • mTORC1 inhibition is one of the most replicated longevity-linked mechanisms in model organisms; this work extends its relevance to a common age-related structural tissue condition.

CLINICALAGE — MODELING BIOLOGICAL AGE FROM HEALTH RECORDS

  • A model development and validation study published in Lancet Digital Health (Lian J. et al.) introduces ClinicalAge, a framework that models aging trajectories from longitudinal electronic health records in the UK, separating biological aging speed from chronological age.
  • A linked commentary in Lancet Digital Health (Zhu LZ, Hu W.) describes a novel aging biomarker derived from electronic health record data that captures individual aging trajectories over time — pointing toward routine clinical biological age monitoring.

AI FACE PHOTOGRAPHS AS AGING BIOMARKERS

  • A model development study in Lancet Digital Health (Haugg F. et al., including Vadim Gladyshev of Harvard) validated a foundation AI model called FAHR-Face that estimates biological age and health status from face photographs, trained across diverse populations.
  • The tool could enable low-cost, scalable biological age screening without blood draws or imaging.

PHYSICAL ACTIVITY AS AN AGING CLOCK

  • A Lancet Healthy Longevity commentary (Suetta C.) argues that physical function and muscle health are more clinically meaningful aging clocks than chronological age, with direct implications for how geriatric risk is assessed and treated.
  • Lancet Healthy Longevity published a coordinated series of reviews (Valenzuela PL, King AC, Izquierdo M. et al.) concluding that physical activity promotion for older adults in low- and middle-income countries is an urgent, underfunded public health priority requiring multilevel policy action.

SENESCENCE-MIMETIC CANCER IMMUNOTHERAPY

  • A study in Biomaterials (Yang Z. et al.) developed hybrid nanovesicle artificial antigen-presenting cells that incorporate senescence-mimetic erythrocyte membrane signals to prime T-cells in the spleen against tumors — combining aging biology mechanisms with cancer immunotherapy design.

ANIMAL PROTEIN, COGNITION, AND DEMENTIA DISPARITIES

  • A global ecological analysis in Future Science OA (You W. et al., published November 2, 2026) found associations between national animal protein supply, cognitive aging trajectories, and female-to-male dementia disparities across countries, adding nutritional variables to the dementia risk picture.

💊 NEW CURES & APPROVALS

TOFACITINIB CITRATE GENERICS — JAK INHIBITOR

  • Two new generic manufacturers received FDA original approvals for tofacitinib citrate: Apotex (ANDA220458) and Dexcel (ANDA218668).
  • Tofacitinib is a JAK1/JAK3 inhibitor used for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; expanded generic competition may reduce cost for patients on long-term immunomodulatory therapy.

OXDERYS (DOXORUBICIN HYDROCHLORIDE) — AVYXA HOLDINGS

  • Avyxa Holdings received an original NDA approval (NDA221093) for Oxderys, an active doxorubicin hydrochloride formulation for oncology indications.
  • Doxorubicin is an anthracycline chemotherapy agent used across multiple tumor types; this represents a new branded formulation entering the market.

GAVRETO (PRALSETINIB) SUPPLEMENTAL — RIGEL PHARMACEUTICALS

  • Rigel Pharmaceuticals received a supplemental approval for Gavreto (pralsetinib, NDA213721), a RET kinase inhibitor used in RET fusion-positive non-small cell lung cancer and RET-mutant thyroid cancers.

PERTUZUMAB BIOSIMILAR POHERDY — SHANGHAI HENLIUS BIOTECH

  • Shanghai Henlius Biotech received a supplemental BLA approval for Poherdy (pertuzumab-dpzb, BLA761450), a biosimilar to Perjeta used in HER2-positive breast cancer.

DAPAGLIFLOZIN / METFORMIN COMBINATION — MICRO LABS

  • Micro Labs received a supplemental ANDA approval (ANDA211466) for the dapagliflozin and metformin hydrochloride combination, used in type 2 diabetes management; dapagliflozin (an SGLT2 inhibitor) also carries cardiovascular and renal mortality reduction indications.

ZOKINVY (LONAFARNIB) SUPPLEMENTAL — SENTYNL THERAPEUTICS

  • Sentynl Therapeutics received a supplemental approval for Zokinvy (lonafarnib, NDA213969), a farnesyltransferase inhibitor used in Hutchinson-Gilford Progeria Syndrome, a rare accelerated-aging disease in children.

🧪 CLINICAL TRIALS

SALANERSEN (BIIB115) FOR SPINAL MUSCULAR ATROPHY — BIOGEN

  • A new ClinicalTrials.gov registration (NCT07444476) is studying salanersen (BIIB115), a Biogen investigational asset, in participants aged 15 to 60 with SMA who are treatment-naive or previously treated with risdiplam, assessing motor function effects and safety.
  • SMA is caused by SMN1 gene loss; salanersen represents a next-generation approach beyond existing approved therapies nusinersen and risdiplam.

ALL-ORAL AML COMBINATION — IDH1 MUTATION

  • A new multicenter exploratory trial (NCT07937124) is evaluating ivosidenib (IDH1 inhibitor) plus sonrotoclax (BCL2 inhibitor) plus chidamide (HDAC inhibitor) as an all-oral regimen in approximately 30 adults with newly diagnosed IDH1-R132 mutant acute myeloid leukemia.

NXT007 FOR PEDIATRIC HEMOPHILIA A — PROPHYLAXIS TRIAL

  • A new ClinicalTrials.gov study (NCT07838194) is evaluating efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis in pediatric patients aged 0 to 11 years with moderate-to-severe congenital hemophilia A without factor VIII inhibitors.

INFLUENZA VACCINATION CHATBOT IN OLDER ADULTS

  • A randomized controlled trial (NCT07934888) is testing whether a combined rule-based chatbot with ChatGPT-supported real-time question-and-answer functions improves seasonal influenza vaccination uptake in community-dwelling adults aged 65 and older.

FRAILTY INDEX FOR HIP FRACTURE OUTCOMES

  • A prospective observational study (NCT07936279) is evaluating the Modified Frailty Index-5 (mFI-5) score as a predictor of ICU admission need and 30-day mortality in patients aged 65 and older undergoing hip fracture surgery — directly linking frailty measurement to geriatric surgical risk.

BLINATUMOMAB IN OLDER ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

  • An ongoing Phase II trial (NCT02143414) continues to study blinatumomab combined with chemotherapy or dasatinib/prednisone in older patients with ALL, testing whether immunotherapy with this bispecific T-cell engager antibody can spare older patients from full-intensity chemotherapy.

📢 PUBLIC HEALTH

DRUG-RESISTANT BACTERIA RISING

  • A CDC report released September 23, 2025 documented a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing antimicrobial resistance as a parallel long-term threat to population longevity.

CONGENITAL SYPHILIS RISES FOR 12TH CONSECUTIVE YEAR

  • CDC data released September 24, 2025 showed U.S. congenital syphilis cases increased for the 12th consecutive year in 2024, representing a persistent failure of prenatal screening and treatment systems.

ONGOING LISTERIA OUTBREAK — PREPARED MEALS

  • CDC continues to warn consumers to check refrigerators and freezers for recalled prepared meal products linked to an ongoing multistate Listeria outbreak; new illnesses and deaths have been added since the initial alert.

COUNTERFEIT ONLINE PHARMACY RISK

  • CDC has flagged an ongoing public health risk from individuals ordering counterfeit prescription medications through unverified online pharmacies, with unknown active ingredients and contamination risks.

BIOMED PULSE is an informational briefing only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Middle East respiratory syndrome (MERS) – Qatar — WHO Disease Outbreak News
  5. Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News
  6. Shamonda virus in human - France — WHO Disease Outbreak News
  7. Pneumonia of undetermined etiology - the Russian Federation — WHO Disease Outbreak News
  8. Yellow fever - WHO African Region — WHO Disease Outbreak News
  9. Yellow fever - Global — WHO Disease Outbreak News
  10. GDF11 restores skeletal muscle satellite cell function via MYC… — Europe PMC — Longevity

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261115-02-v137 · 2026-11-15 02:01 UTC · pulse.uzylab.com